Trial Profile

A proof of concept trial of BHV-2100 for treatment of neuropathic pain

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV-2100 (Primary)
Indications Neuropathic pain
Focus Proof of concept; Therapeutic Use

Most Recent Events

09 May 2024 According to a Biohaven Pharmaceutical Holding Company media release, pharmacokinetic data in Phase 1 studies, presented in Oral and poster presentations at AAN showcased breadth of development work across the platform.
16 Jan 2024 New trial record
08 Jan 2024 According to a Biohaven Pharmaceutical Holding Company media release, the company plans to initiate this trial in 2H 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com